Guangzhou Kangrui Tai Pharmaceutical Co., Ltd. is a company founded by a number of America PhD specializing in organic synthesis and technology development of high-tech enterprises, the company founder digits in Pfizer, Merck, Roche and Genentech, the world's top pharmaceutical company has accumulated more than 50 years The working experience, can offer 1.1 tough patent generic drugs and new drug technology development services to pharmaceutical and biotechnology companies at home and abroad. Use to avoid patent barriers to foreign companies setting, self-developed proprietary synthetic process, the company is committed to the production and sale of API intermediates. Founded in 2012, R & D headquarters is located in the high-tech industry gathering in Guangzhou Science City, and has regional branches in California. Guangzhou Development Zone as a leading talent, the company has set up a high-quality management, research and development, quality control and marketing professionals, and to develop a scientific training system and effective incentive promotion system. Existing staff of 50 people, about 30 percent have a doctorate or master's degree, undergraduate academic staff accounted for more than 80%. To further enhance the company's overall strength, the company hired a number of well-known experts in pharmaceutical chemistry and technology research in the field of science and technology as the company's advisor. The company has developed more than 1,600 square meters of space, in accordance with international standards of construction has two rooms can accommodate 34 chemical reaction synthesis laboratory fume hood and a well-equipped with four 50 liters kettle kilo lab, also has a feature a liquid chromatography-mass spectrometry, high standard gas chromatography, liquid chromatography, and other advanced analytical quality control equipment testing center. As a research and development, production and sales of raw materials drug intermediates business, the company currently has a number of patent achievements in synthesis of APIs and other aspects of process development. The company has successfully developed antibacterials - sitafloxacin, anti-cancer drugs - the first left boron meters, the production process. The company set up nearly 10,000 square meters of production base, the reactor is equipped with dozens of 200 rose to 5000 liters, with from pilot to industrial scale production capacity, and has achieved sitafloxacin three-membered ring side chain, ring industrialization propyl bromide and 3-oxetanone and other large-scale production of pharmaceutical intermediates. Since its inception, leading to the synthesis process, safe production facilities and increasingly comprehensive service system, is committed to providing global customers with fast and high-quality drug development services.